The effects of platelet inhibitors on blood use in cardiac surgery

Perfusion

Volumn 17, Issue 1, 2002, Pages 33-37

  Lee, Leonard Y ^a   DeBois, William ^a   Krieger, Karl H ^a   Girardi, Leonard N ^a   Russo, Laura ^a   McVey, James ^a   Ko, Wilson ^a   Altorki, Nasser K ^a   Brodman, Richard A ^a   Isom, O Wayne ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN;

BLOOD TRANSFUSION; DRUG ANTAGONISM; HEART SURGERY; HUMAN; IMMUNOLOGY; METHODOLOGY; REVIEW; UTILIZATION REVIEW; ARTICLE; BLEEDING; BLEEDING TIME; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG WITHDRAWAL; EMERGENCY SURGERY; GRAFT PATENCY; HEART INFARCTION; MEDICAL SPECIALIST; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SAFETY; THROMBOCYTE; THROMBOCYTE TRANSFUSION; TREATMENT PLANNING; ULTRAFILTRATION;

BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 18244397237     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1191/0267659102pf532oa     Document Type: Article

References (23)

1. Antiplatelet agents in cardiology: The choice of therapy
2. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty
3. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators
4. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of platelet IIb/IIIa ischemic complication
5. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
6. Enhancement of the safety of coronary stenting with the use of abciximab, a platelet glycoprotein IIb/IIIa inhibitor
7. Is bleeding risk increased in patients undergoing urgent coronary artery bypass surgery following abciximab?
8. Resternotomy for bleeding after cardiac operation: A marker for increased morbidity and mortality
9. Reexploration for bleeding is a risk for adverse outcomes after cardiac operations
10. Clopidogrel loading dose regimens: Kinetic profile of pharmacodynamic response in healthy subjects
11. Clopidogrel: A review of its use in the prevention of atherothrombosis
12. GP IIb/IIIa antagonists: Pathophysiologic and therapeutic insights from studies of c7E3 Fab
13. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations
14. Prediction of creatinine clearance from serum creatinine
15. Bleeding complications with the chimeric antibody to platelet Gp IIb/IIIa integrin in patients undergoing percutaneous coronary intervention
16. A possible method to control prolongation of bleeding time under antiplatelet therapy with ticlopidine
17. Aprotinin reduces clopidogrel induced prolongation of the bleeding time in the rat
18. Platelet inhibitors and bleeding in cardiac surgical patients
19. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers
20. Anticoagulation monitoring during cardiac surgery: A survey of current practice and review of current and emerging techniques
21. High-volume, zero-balanced hemofiltration to reduce delayed inflammatory response to cardiopulmonary bypass in children
22. Reopro removal during cardiopulmonary bypass using a hemoconcentrator
23. Abciximab (Reopro) removal during cardiopulmonary bypass with a hemoconcentrator